Oliver Dorigo, MD, PhD
There are more than 1000 investigational immunotherapy combinations being explored in the ovarian cancer space; of these agents, ones with PARP inhibitors have shown notable activity, explained Oliver Dorigo, MD, PhD.
In the phase I/II TOPACIO/KEYNOTE-162 study, patients with recurrent ovarian cancer were treated with the combination of niraparib (Zejula) and pembrolizumab (Keytruda). The overall response rate (ORR) was 25% among 60 patients who were eligible for evaluation. Of those who harbored BRCA
mutations (n = 12), the ORR was 42%.
Niraparib is currently approved by the FDA as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
... to read the full story